Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Refined C-Reactive Protein Cutoffs Help Assess Sepsis Risk in Preterm Babies

By LabMedica International staff writers
Posted on 02 Dec 2025

Early-onset sepsis (EOS) is a dangerous bloodstream infection that appears in the first three days of life, yet its early symptoms resemble many benign newborn conditions. More...

To support urgent treatment decisions, clinicians often turn to C-reactive protein (CRP). While CRP is widely used and has a strong negative predictive value, its optimal cutoffs during the first 72 hours of life have been unclear. A multicenter retrospective study now offers a clearer solution by defining time- and gestation-specific CRP thresholds that help identify which newborns—particularly preterm infants—are most likely to have EOS.

In the study conducted at The Chinese University of Hong Kong (Hong Kong SAR), researchers reviewed electronic health records across all public hospitals to evaluate CRP’s diagnostic performance in more than 100,000 newborns over 11 years. The investigators found that CRP rises naturally after birth in healthy babies, peaking around 24 to 32 hours, and this rise is markedly higher in term infants.

Because of this physiological spike, elevated CRP values early in life may not signal infection in term newborns and can lead to unnecessary antibiotic exposure. In contrast, CRP proved far more reliable in preterm infants. A cutoff above 8.0 mg/L after four hours of life identified infection with strong diagnostic performance among babies born before 34 weeks. For early-onset meningitis, a CRP level greater than 12.0 mg/L showed high specificity and strong negative predictive value, helping rule out disease.

The findings emphasize that CRP should not be interpreted using a universal cutoff for all newborns. Instead, clinicians must account for gestational age, timing of sampling, and the expected physiological rise after birth. Used selectively—especially in preterm infants—CRP can provide meaningful support in EOS screening and help guide when to pursue further testing for meningitis.

“Ours is the first population-based study to evaluate how well CRP testing can identify EOS in newborns, highlighting the fluctuations of CRP levels in a real-world setting,” said Prof. Hugh Simon Lam, who led the research team. “Although CRP isn’t a perfect biomarker for EOS detection, it can still help assess infection risk in preterm babies and guide clinicians on whether further testing for meningitis is needed.”

Related Link
The Chinese University of Hong Kong


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.